Key Research Papers and Clinical Trials

Recent research on liraglutide, a GLP-1 receptor agonist, spans multiple therapeutic areas and delivery methods. The available evidence includes both completed clinical trials and emerging research studies, though detailed results are not provided for most citations.

Clinical Trials

Several Phase 3 and Phase 4 trials have been completed examining liraglutide's effectiveness. A completed Phase 3 trial (NCT00518882) compared liraglutide to exenatide when added to existing diabetes treatments, though specific outcomes and sample sizes are not detailed in the available evidence.

Additional Phase 4 studies have examined liraglutide's long-term efficacy. One completed trial (NCT02730377) compared liraglutide plus metformin versus other oral antidiabetic drugs plus metformin over 104 weeks of treatment in type 2 diabetes patients. Another Phase 4 study (NCT02910570) investigated changes in skin autofluorescence following weight loss with liraglutide treatment in knee osteoarthritis patients, suggesting research into applications beyond diabetes.

Currently, a Phase 4 trial (NCT07244003) is recruiting patients to study the combination of metformin, SGLT-2 inhibitors, and GLP-1 receptor agonists in type 2 diabetes patients with poor glycemic control.

Recent Research Studies

Recent studies published in 2026 explore various aspects of liraglutide therapy. Research has examined novel delivery methods, including zein-based nanoparticles for combined oral delivery of insulin and liraglutide, with preliminary testing in zebrafish models.

Comparative effectiveness research has investigated GLP-1 receptor agonists versus oral medications for insulin discontinuation in type 2 diabetes using target trial emulation methods. Another study compared IDegLira (a combination of insulin degludec and liraglutide) with insulin glargine for short-term intensive therapy in overweight or obese type 2 diabetes patients.

Network meta-analyses have examined the cardiovascular safety profile of GLP-1 receptor agonists, including their effects on ventricular arrhythmias and cardiovascular events. Basic science research has explored liraglutide's protective mechanisms against pancreatic islet injury, specifically its inhibition of HMGB1 release in streptozotocin-induced models.

Reproductive Health Research

Emerging research has begun examining GLP-1 receptor agonists' effects on reproductive health, including studies on fertility outcomes and menstrual events in reproductive-aged patients. However, the available evidence provides limited detail about study designs, sample sizes, or specific findings.

Note: This synthesis is based on citation information only, as detailed study results were not provided in the evidence. For clinical decision-making, healthcare providers should consult the full published studies and established clinical guidelines.